Biotech
Eikon Therapeutics
Eikon Therapeutics raises $106M Series C at $1B valuation
$106M
Total Raised
Series C
Latest Round
2019
Founded
150+
Employees
Hayward, CA
1 min read
Quick Facts
Valuation
$1B
Latest Round Size
$106M
Latest Round Date
September 2024
Eikon Therapeutics: Series C Funding Round
Eikon Therapeutics has successfully raised $106M in Series C funding, reaching a valuation of $1B.
Company Overview
Biotech startup developing cancer-fighting therapeutic assets
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Two Sigma Ventures.
Company Information
- Headquarters: Hayward, CA
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Eikon Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Two Sigma Ventures: Verified investor in Series C
Key Investors
ARCH Venture Partners
Lead Investor
Verified investor in Series C
Two Sigma Ventures
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M